![]() ![]() So we hired I want to say about 275 people last year, mostly, I would say almost entirely over zoom. I never in my wildest dreams, I don't know about you guys thought I would ever hire anybody without meeting them in person. But I think more specifically, let's start with the beginning of the journey, which is recruiting. Maybe the easier question to answer is what's the same, because that would be one word, which is nothing. How have you, Leslie, start with you? How have you started thinking about leading since January 2020? What are the dynamics that you're really plugged into that? Maybe were not on your radar screen before? And from the investment community as well. And as leaders in med tech right now, publicly traded company rapidly growing company soon to see if it goes public or not never know. ![]() We were having some great conversations beforehand. So I really appreciate all you joining us here. I'm excited for this panel representing leadership in the med tech health tech industry. The company’s rapid growth and aspirational objectives are driving a shift in the market and my goal is to help accelerate that.Well, thanks for joining me here at LSI 2022. “Outset is not only leading the charge when it comes to reimagining dialysis for both patients and providers, but also catalyzing change in the entire dialysis care delivery model. “I’ve spent most of my career focused on innovations around patient care and I’ve witnessed firsthand the impact medical technology can have on people’s lives,” said Szyman. She previously served on the pre-IPO boards of Tornier and Inspire Medical Systems. Szyman currently serves on the board of directors at Inari Medical (NASDAQ: NARI), the American Heart Association of Orange County, and on the board of governors at Opus College of Business at the University of St. Earlier in her Medtronic tenure, she drove the company’s endovascular business revenue by more than 300 percent to $250 million in four years. In her five years there, she successfully grew the global diabetes business unit more than 40 percent to $1.5B in revenue. Prior to that, Szyman served as Senior Vice President and President of Medtronic Diabetes. In her current role at Edwards, Szyman is focused on new, innovative technologies and has grown the critical care business almost 50 percent to $800M within six years. “Her commercial growth acumen both in the critical care and consumer diabetes space reflects our focus on transforming the dialysis experience for patients and providers in both the acute and home setting.” “Katie’s impressive track record of ushering medical device companies through market expansion and high growth is ideally suited to Outset,” said Outset Medical CEO Leslie Trigg. ![]() With a focus on driving sustainable, high-growth revenue, Szyman has introduced to market patient-focused innovations that also drive cost efficiencies for providers. Szyman, currently Corporate Vice President and General Manager of Critical Care at Edwards Lifesciences, brings more than 30 years of global medtech leadership experience. ![]() Outset Medical, Inc., a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, today announced the appointment of Katie Szyman to its board of directors. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |